NSD3 , a member of nuclear receptor‐binding SET domain family, is a potential prognostic biomarker for pancreatic cancer
Cancer Medicine · 2023
DOI: 10.1002/cam4.5774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Qunli Xiong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Histones, Pancreatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Members of the nuclear receptor‐binding SET domain (NSD) family of histone H3 lysine 36 methyltransferases comprise NSD1, NSD2 (MMSET/WHSC1), and NSD3 (Wolf–Hirschhorn syndrome candidate 1‐like 1, WHSC1L1). While the expression of NSD genes is essential to normal biological processes and cancer, knowledge of their expression levels to prognosticate in cancer remains unclear.
Methods
We analyzed the expression patterns for NSD family genes across multiple cancer types and examined their association with clinical features and patient survival profiles. Next, we explored the association between NSD3 expression and described features of the tumor microenvironment (TME) in PAAD, a severe type of pancreatic cancer. In particular, we correlated promoter methylation levels for NSD3 with patient outcomes in PAAD. Finally, we explored the putative oncogenic roles for NSD3 using a series of experiments with pancreatic cancer cells.
Results
We report that the expression of NSD family members is correlated with clinical prognosis across multiple types of cancers. Also, we demonstrate that NSD3 variants are most prevalent among NSD genes across cancers we analyzed. Notably, when compared with NSD1 and NSD2, we find that NSD3 is prominently expressed, and its expression is significantly linked with clinical outcome in pancreatic cancer. Furthermore, NSD3 is frequently amplified, exhibits low promoter methylation, and is correlated with immune cell infiltration and enhanced proliferation of pancreatic cancer. Finally, we demonstrate that knockdown of NSD3 alters H3K36me2 methylation, downstream gene expression and EGFR/ERK signaling in pancreatic cancer cells.
Conclusions
We find that expression levels, the presence of genetic variants of NSD family genes, as well as their promoter methylation are correlated with clinical outcomes in cancer, including pancreatic cancer. Our in vitro experiments suggest that NSD3 may be relevant to gene expression regulation and growth factor signaling in pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China.
- Research Laboratory of Cancer Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan Uni…
- Department of Radiation Oncology, Shaanxi Provincial People's Hospital, Xi'an, China.
ORCID-Profile: Qunli Xiong, Qing Zhu
Zitieren
APA
Xiong, Q., Zhou, Y., Zhang, S., Zhang, Y., Xu, Y., Yang, Y., Zhou, C., Zeng, Z., Han, J., & Zhu, Q. (2023). NSD3 , a member of nuclear receptor‐binding SET domain family, is a potential prognostic biomarker for pancreatic cancer. Cancer Medicine. https://doi.org/10.1002/cam4.5774
Vancouver
Xiong Q, Zhou Y, Zhang S, Zhang Y, Xu Y, Yang Y, et al. NSD3 , a member of nuclear receptor‐binding SET domain family, is a potential prognostic biomarker for pancreatic cancer. Cancer Medicine. 2023. doi:10.1002/cam4.5774
BibTeX
@article{Xiong2023,
author = {Xiong, Qunli and Zhou, Ying and Zhang, Su and Zhang, Yaguang and Xu, Yongfeng and Yang, Yang and Zhou, Congya and Zeng, Zhu and Han, Junhong and Zhu, Qing},
title = {NSD3 , a member of nuclear receptor‐binding SET domain family, is a potential prognostic biomarker for pancreatic cancer},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5774}
}
EUVIMED